Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy
Can an old, cheap generic obesity drug pulled years ago from the US market be tweaked and made over into a brand new therapeutic able to compete for a share of the multibillion-dollar ADHD market?
NLS Pharma aims to find that out.
Mazindol was first developed way back in the 1960s by Sandoz as an immediate-release obesity drug designed to shed pounds fast. A little less than a decade ago, the FDA determined that while the therapy — sold as Sanorex — had been pulled from the US market, it wasn’t due to safety or efficacy reasons, leaving it wide open to a generic application from a discount supplier.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.